What do patients really think about their meds? Ask Drug-GPT
A Glasgow-based health data tech company has developed a new tool, Drug-GPT, which claims to provide curated insights into doctor and patient views on various medications.
Last year, Talking Medicines released AI platform Patient MetRx, which scrapes data from millions of online social media conversations to find out what patients are saying about drugs they’ve taken.
The platform uses machine learning and natural language processing with the goal of providing useful KPIs for health marketing agencies and pharmaceutical firms.
Now, the firm – which started life in 2013 as a consultancy for a pharma – has just released a new version of the platform with new ‘Drug-GPT’ tool that claims to produce fully rounded curated reports on drugs based on patient and health care professional (HCP) data “within seconds”.
The firm also claims that these insights are “fully compliant with health sector regulations and backed by a suite of quality control processes”.
The GPT models are licenced from Microsoft, the firm claims, to ensure that the ecosystem around Drug-GPT is closed.
The insights gathered by the tool, claimed Talking Medicines, “helps agencies inform new business pitches, develop winning strategies, create creative content and monitor the impact of critical market events on customer behaviour”.
Other new Patient MetRx features include a curated health care practitioner option that complements the patient option as well as a new natural language search feature that promises “fast, data-led questioning of curated data”.
According to Talking Medicines, feedback from current users suggests that the platform is 80% more effective than conventional methods at producing structured and actionable insights.
The firm’s CEO Jo Halliday claimed that the tool would transform the way that healthcare advertising agencies analyse insights on complex patient and HCP social data.
“With structured and actionable insights delivered within seconds, it provides our customers with the edge to win business, create amazing content, and deliver successful campaigns,” she added.
Last year Talking Medicines secured a £1.5m funding round to support its expansion into the US and it now has a New Jersey office.
Subscribe to our Editor's weekly newsletter